RSS feed

Publications (original articles or review articles) published in 2023 from OUS - Department of Oncology

19 publications found

Blakstad H, Brekke J, Rahman MA, Arnesen VS, Miletic H, Brandal P, Lie SA, Chekenya M, Goplen D (2023)
Survival in a consecutive series of 467 glioblastoma patients: Association with prognostic factors and treatment at recurrence at two independent institutions
PLoS One, 18 (2), e0281166
DOI 10.1371/journal.pone.0281166, PubMed 36730349

Boye K, Gorunova L, Gunawan B, Hompland I, Sander B, Panagopoulos I, Langer C, Golas M, Heim S, Füzesi L, Hølmebakk T, Micci F (2023)
Genomic Complexity as a Biomarker to De-Escalate Adjuvant Imatinib Treatment in High-Risk Gastrointestinal Stromal Tumor
JCO Precis Oncol, 7, e2200351
DOI 10.1200/PO.22.00351, PubMed 36724411

Dahl AA, Bentzen AG, Fosså SD, Hess SL, Kiserud CE (2023)
A study of modifiable factors associated with health-related quality of life in long-term cervical cancer survivors
Acta Obstet Gynecol Scand, 102 (2), 218-225
DOI 10.1111/aogs.14490, PubMed 36683549

Eikeland SA, Smeland KB, Simensen VC, Fagerli UM, Bersvendsen HS, Kiserud CE, Fosså A (2023)
Chronic fatigue in long-term survivors of Hodgkin's lymphoma after contemporary risk-adapted treatment
Acta Oncol, 1-9 (in press)
DOI 10.1080/0284186X.2023.2168215, PubMed 36715320

Garset-Zamani M, von Buchwald C, Karevold G, Agander TK, Mateu-Regué À, Eide HA, Tvedskov JF (2023)
An HPV-Vaccinated Patient With Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma
JAMA Otolaryngol Head Neck Surg, 149 (1), 92-94
DOI 10.1001/jamaoto.2022.3762, PubMed 36416857

Hjermstad MJ, Aass N, Gravli TH, Smeland S, Kaasa S (2023)
[Not Available]
Tidsskr Nor Laegeforen, 143 (1)
DOI 10.4045/tidsskr.22.0668, PubMed 36655956

Huuhtanen J, Kasanen HH, Peltola K, Lönnberg T, Glumoff V, Brück O, Dufva O, Peltonen K, Vikkula J, Jokinen E, Ilander M, Lee MH, Mäkelä S, Nyakas M, Li B, Hernberg M, Bono P, Lähdesmäki H, Kreutzman A, Mustjoki S (2023)
Single-cell characterization of anti-LAG3+anti-PD1 treatment in melanoma patients
J Clin Invest (in press)
DOI 10.1172/JCI164809, PubMed 36719749

Juzeniene A, Stenberg VY, Bruland ØS, Revheim ME, Larsen RH (2023)
Dual targeting with ²²⁴Ra/²¹²Pb-conjugates for targeted alpha therapy of disseminated cancers: A conceptual approach
Front Med (Lausanne), 9, 1051825
DOI 10.3389/fmed.2022.1051825, PubMed 36733936

Lilleby W, Seierstad T, Inderberg EM, Hole KH (2023)
Impact of human telomerase reverse transcriptase peptide vaccine combined with androgen deprivation therapy and radiotherapy in de novo metastatic prostate cancer: Long-term clinical monitoring
Int J Cancer (in press)
DOI 10.1002/ijc.34448, PubMed 36715014

Normann LS, Haugen MH, Hongisto V, Aure MR, Leivonen SK, Kristensen VN, Tahiri A, Engebraaten O, Sahlberg KK, Mælandsmo GM (2023)
High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer
PLoS One, 18 (1), e0280507
DOI 10.1371/journal.pone.0280507, PubMed 36706086

Ottesen JA, Yi D, Tong E, Iv M, Latysheva A, Saxhaug C, Jacobsen KD, Helland Å, Emblem KE, Rubin DL, Bjørnerud A, Zaharchuk G, Grøvik E (2023)
2.5D and 3D segmentation of brain metastases with deep learning on multinational MRI data
Front Neuroinform, 16, 1056068
DOI 10.3389/fninf.2022.1056068, PubMed 36743439

Piperno-Neumann S, Carlino MS, Boni V, Loirat D, Speetjens FM, Park JJ, Calvo E, Carvajal RD, Nyakas M, Gonzalez-Maffe J, Zhu X, Shirley MD, Ramkumar T, Fessehatsion A, Burks HE, Yerramilli-Rao P, Kapiteijn E (2023)
A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma
Br J Cancer (in press)
DOI 10.1038/s41416-022-02133-6, PubMed 36624219

Sanchez VA, Shuey MM, Dinh PC, Monahan PO, Fosså SD, Sesso HD, Dolan ME, Einhorn LH, Vaughn DJ, Martin NE, Feldman DR, Kroenke K, Fung C, Frisina RD, Travis LB (2023)
Patient-Reported Functional Impairment Due to Hearing Loss and Tinnitus After Cisplatin-Based Chemotherapy
J Clin Oncol, JCO2201456 (in press)
DOI 10.1200/JCO.22.01456, PubMed 36626694

Schipmann-Miletic S, Sivakanesan S, Rath DS, Brandal P, Vik-Mo E, Bjørås M, Solheim O, Ingebrigtsen T, Sund F, Bjerkvig R, Miletic H, Johannessen TA, Sundstrøm T (2023)
[Not Available]
Tidsskr Nor Laegeforen, 143 (2)
DOI 10.4045/tidsskr.22.0314, PubMed 36718891

Schmid MP, Lindegaard JC, Mahantshetty U, Tanderup K, Jürgenliemk-Schulz I, Haie-Meder C, Fokdal LU, Sturdza A, Hoskin P, Segedin B, Bruheim K, Huang F, Rai B, Cooper R, van der Steen-Banasik E, Van Limbergen E, Pieters BR, Petric P, Ramazanova D, Ristl R, Kannan S, Hawaldar R, Ecker S, Kirchheiner K, Tan LT et al. (2023)
Risk Factors for Local Failure Following Chemoradiation and Magnetic Resonance Image-Guided Brachytherapy in Locally Advanced Cervical Cancer: Results From the EMBRACE-I Study
J Clin Oncol, JCO2201096 (in press)
DOI 10.1200/JCO.22.01096, PubMed 36599120

Skoie IM, Skogås JG, Langø T, Myhr KM, Myhre PL, Goll R, Fretland SØ, Helland Å (2023)
New centres to carry out more clinical trials in Norway
Tidsskr Nor Laegeforen, 143 (2)
DOI 10.4045/tidsskr.22.0722, PubMed 36718905

Spampinato S, Tanderup K, Lindegaard JC, Schmid MP, Sturdza A, Segedin B, Jürgenliemk-Schulz IM, De Leeuw A, Bruheim K, Mahantshetty U, Chargari C, Rai B, Cooper R, van der Steen-Banasik E, Sundset M, Wiebe E, Villafranca E, Van Limbergen E, Pieters BR, Tee Tan L, C H W Lutgens L, Hoskin P, Smet S, Pötter R, Nout R et al. (2023)
Association of persistent morbidity after radiotherapy with quality of life in locally advanced cervical cancer survivors
Radiother Oncol, 109501 (in press)
DOI 10.1016/j.radonc.2023.109501, PubMed 36720348

Trøseid M, Arribas JR, Assoumou L, Holten AR, Poissy J, Terzić V, Mazzaferri F, Baño JR, Eustace J, Hites M, Joannidis M, Paiva JA, Reuter J, Püntmann I, Patrick-Brown TDJH, Westerheim E, Nezvalova-Henriksen K, Beniguel L, Dahl TB, Bouscambert M, Halanova M, Péterfi Z, Tsiodras S, Rezek M, Briel M et al. (2023)
Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial
Crit Care, 27 (1), 9
DOI 10.1186/s13054-022-04205-8, PubMed 36627655

Vittrup AS, Kirchheiner K, Pötter R, Fokdal LU, Jensen NBK, Spampinato S, Haie-Meder C, Schmid MP, Sturdza A, Mahantshetty U, Hoskin P, Segedin B, Bruheim K, Rai B, Wiebe E, van der Steen-Banasik E, Cooper R, Van Limbergen E, Sundset M, Pieters BR, Kirisits C, Lindegaard JC, Jürgenliemk-Schulz IM, Nout R, Tanderup K et al. (2023)
Overall severe morbidity after chemo-radiotherapy and MRI guided adaptive brachytherapy in locally advanced cervical cancer: results from the EMBRACE-I study
Int J Radiat Oncol Biol Phys (in press)
DOI 10.1016/j.ijrobp.2023.01.002, PubMed 36641039